Results 191 to 200 of about 35,714,339 (381)
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
, 2021 Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Reyes Bernabé, Linda Coate, Mariano Provencio, Rosario García Campelo, Sinéad Cuffe, Sayed M.S. Hashemi, Martin Früh, Bartomeu Massutí, José García-Sánchez, Manuel Dómine, Margarita Majem, J.M. Sánchez-Torres, Christian Britschgi, Miklos Pless, Georgia Dimopoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, Rafael Rosell, Rolf A. Stahel, Solange Peters, Rolf A. Stahel, Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Reyes Bernabé, Mariano Provencio, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho +99 moreopenalex +2 more sourcesScreening for lung cancer: A systematic review of overdiagnosis and its implications
Molecular Oncology, EarlyView.Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto +12 morewiley +1 more sourceA Multisite Randomized Controlled Two-Phase Trial of the Early Start Denver Model Compared to Treatment as Usual
, 2019 Sally J. Rogers, Annette Estes, Catherine Lord, Jeff Munson, Marie Rocha, Jamie Winter, Jessica Greenson, Costanza Colombi, Géraldine Dawson, Laurie A. Vismara, Catherine A. Sugar, Gerhard Hellemann, Fiona Whelan, Meagan R. Talbott +13 moreopenalex +2 more sourcesGlycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala +18 morewiley +1 more sourcePER1 Serves as a Tumor Suppressor in Breast Cancer by Regulating MEK5/ERK5 Signaling Pathway
International Journal of General MedicineYinfeng Liu,1 Dandan Yang,2 Zihang Xu,1 Ji Lv,1 Zizheng Wu,1 Jie Zheng,1,3 Meng Han,1 Guanli Yuan4 1Breast Disease Diagnosis and Treatment Center, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, People’s Republic of China; 2Clinical Laboratory ...Liu Y, Yang D, Xu Z, Lv J, Wu Z, Zheng J, Han M, Yuan G +7 moredoaj CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane +12 morewiley +1 more source
